---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-279648"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:19:10.046135+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Taysha Q3 net loss narrows to $26.3M; Astellas $50M investment extends cash runway

## Summary
- Net loss $26.3M ($0.64/sh) vs $51.2M ($1.35/sh) Q3 2021; R&D expenses down to $16.4M.
- Astellas invests $50M for 15% stake, options to license TSHA-120 (GAN) and TSHA-102 (Rett).
- Cash $34.3M at Sept 30; plus Astellas $50M and $25.6M net from Oct offering, runway into Q1 2024.
- Type B end-of-Phase 2 FDA meeting for TSHA-120 on Dec 13, 2022; regulatory update in Jan 2023.
- Preliminary TSHA-102 adult data and pediatric trial start expected in H1 2023.

## SEC filing metadata
- accession: 0001193125-22-279648
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/0001193125-22-279648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/d411971d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-279648
- JSON: https://secwatch.observer/filing/0001193125-22-279648.json
- Plain text: https://secwatch.observer/filing/0001193125-22-279648.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/0001193125-22-279648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.